3133 related articles for article (PubMed ID: 20579941)
21. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
22. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
[TBL] [Abstract][Full Text] [Related]
23. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
24. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
[TBL] [Abstract][Full Text] [Related]
25. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
26. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
Bonaccorsi L; Nesi G; Nuti F; Paglierani M; Krausz C; Masieri L; Serni S; Proietti-Pannunzi L; Fang Y; Jhanwar SC; Orlando C; Carini M; Forti G; Baldi E; Luzzatto L
J Endocrinol Invest; 2009 Jul; 32(7):590-6. PubMed ID: 19494719
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
28. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.
Marx A; Luebke AM; Clauditz TS; Steurer S; Fraune C; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Möller-Koop C; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Meiners J
Dis Markers; 2020; 2020():7050146. PubMed ID: 32377272
[TBL] [Abstract][Full Text] [Related]
30. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract][Full Text] [Related]
31. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
33. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
[TBL] [Abstract][Full Text] [Related]
34. Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.
Kamradt J; Jung V; Wahrheit K; Tolosi L; Rahnenfuehrer J; Schilling M; Walker R; Davis S; Stoeckle M; Meltzer P; Wullich B
PLoS One; 2007 Aug; 2(8):e769. PubMed ID: 17712417
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.
Liu W; Chang B; Sauvageot J; Dimitrov L; Gielzak M; Li T; Yan G; Sun J; Sun J; Adams TS; Turner AR; Kim JW; Meyers DA; Zheng SL; Isaacs WB; Xu J
Genes Chromosomes Cancer; 2006 Nov; 45(11):1018-32. PubMed ID: 16897747
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
[TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
39. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
40. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]